Results 1 to 10 of about 10,230 (140)

Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview

Pharmaceuticals, 2021
Primary brain tumors (PBTs) are some of the most difficult types of cancer to treat, and despite advancements in surgery, chemotherapy and radiotherapy, new strategies for the treatment of PBTs are needed, especially for those with poor prognosis such as
Andrea Cimini, Maria Ricci, Francesca Russo, Martina Egidi, Ferdinando Calabria, Antonio Bagnato, Orazio Schillaci, Agostino Chiaravalloti   +7 more
doaj   +3 more sources

Role of 18F-AlF-NOTATATE PET/CT in selecting pediatric neuroblastoma candidates for 177Lu-DOTATATE peptide receptor radionuclide therapy [PDF]

Frontiers in Medicine
BackgroundNeuroblastoma is the most common extracranial solid tumor in children. Peptide receptor radionuclide therapy (PRRT) is a treatment modality with great potential, however, the predictive indicators for its efficacy remain unclear. The aim of the
Yuxuan Liu, Yingying Sun, Yingying Sun, Di Zuo, Han Wang, Fei Zheng, Jingfu Wang, Xiaorong Sun   +7 more
doaj   +2 more sources

Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy [PDF]

Frontiers in Oncology
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs
Turgut Bora Cengiz, Raksha Kulkarni, Virginia Corbett, Nasrin V. Ghesani, Edward Wolin, Munir V. Ghesani   +5 more
doaj   +2 more sources

Thrombotic Microangiopathy From Peptide Receptor Radionuclide Therapy [PDF]

Kidney International Reports
Paul Delalande, Mickael Bobot, Marie Essig, Corinne Simon, Annie-Pierre Jonville-Béra, Christelle Barbet, Bénédicte Sautenet, Valentin Maisons, Thibaut Carsuzaa, Franck Bruyère, Jean-Michel Halimi   +10 more
doaj   +2 more sources

Peptide Receptor Radionuclide Therapy in Thyroid Cancer

Frontiers in Endocrinology, 2022
The treatment options that are currently available for management of metastatic, progressive radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary thyroid cancers (MTCs) are limited.
Sriram Gubbi, Christian A. Koch, Christian A. Koch, Joanna Klubo-Gwiezdzinska   +3 more
doaj   +1 more source

Peptide receptor radionuclide therapy of neuroendocrine tumors: Case series [PDF]

Archive of Oncology, 2012
Background: Peptide Receptor Radionuclide Therapy (PRRT) is novel and efficacious treatment of neuroendocrine tumors (NETs). Methods: Twenty-seven patients (14 females, 13 males, mean age 54.37±11.14 years; range 30-74 years) with progressive ...
Matović Milovan
doaj   +1 more source

Preclinical study of a new 177Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2020
Objective(s): Somatostatin receptor-positive neuroendocrine tumors have been targeted using various peptide analogs radiolabeled with therapeutic radionuclides for years.
Hossein Behnammanesh, Mostafa Erfani, Maliheh Hajiramezanali, Safura Jokar, Parham Geramifar, Omid Sabzevari, Mohsen Amini, Mohammad Mazidi, Davood Beiki   +8 more
doaj   +1 more source

Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT

Current Oncology, 2021
Peptide receptor radionuclide therapy (PRRT) is used to treat patients with advanced malignant pheochromocytomas (PCCs) and paragangliomas (PGLs).
Erica S. Tsang, Gayle Funk, Janet Leung, Grace Kalish, Hagen F. Kennecke   +4 more
doaj   +1 more source

Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor

Case Reports in Oncology, 2020
Tumor-induced osteomalacia is a very rare paraneoplastic syndrome. It can be caused by phosphaturic mesenchymal tumor (PMT), a generally benign tumor that produces fibroblast growth factor 23 (FGF-23), which can cause a severe renal phosphate wasting ...
Simon Häfliger, Ann-Katrin Seidel, Eric Schoch, Jan Reichmann, Damian Wild, Stephanie Steinmann-Schwager, Miklos Pless   +6 more
doaj   +1 more source

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Cancer Medicine, 2021
Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors.
Marianne S. Elston, Amanda Love, Dev Kevat, Richard Carroll, Zhen Rong Siow, Sharon Pattison, Veronica Boyle, Eva Segelov, Andrew H. Strickland, David Wyld, Richard Gauci, Kim Kennedy, David Ransom, the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)   +13 more
doaj   +1 more source